Navidea Biopharmaceuticals Stock Performance
| NAVB Stock | USD 0.0001 0.00 0.00% |
Navidea Biopharmaceutica holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.58, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Navidea Biopharmaceutica will likely underperform. Use Navidea Biopharmaceutica variance, as well as the relationship between the skewness and day typical price , to analyze future returns on Navidea Biopharmaceutica.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Navidea Biopharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, Navidea Biopharmaceutica sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4.2 M |
Navidea |
Navidea Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 0.01 in Navidea Biopharmaceuticals on July 20, 2025 and sell it today you would earn a total of 0.00 from holding Navidea Biopharmaceuticals or generate 0.0% return on investment over 90 days. Navidea Biopharmaceuticals is currently generating 7.0769% in daily expected returns and assumes 56.145% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Navidea, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Navidea Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Navidea Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Navidea Biopharmaceuticals, and traders can use it to determine the average amount a Navidea Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | NAVB | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 56.15 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Navidea Biopharmaceutica is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Navidea Biopharmaceutica by adding it to a well-diversified portfolio.
Navidea Biopharmaceutica Fundamentals Growth
Navidea Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Navidea Biopharmaceutica, and Navidea Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Navidea Pink Sheet performance.
| Return On Equity | -11.0 | |||
| Return On Asset | -1.22 | |||
| Current Valuation | 3.5 M | |||
| Shares Outstanding | 100.08 M | |||
| Price To Earning | 0.53 X | |||
| Price To Book | 8.16 X | |||
| Price To Sales | 84.14 X | |||
| Revenue | 65.65 K | |||
| EBITDA | (14.05 M) | |||
| Cash And Equivalents | 328.01 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.43 M | |||
| Debt To Equity | 1.20 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (8.99 M) | |||
| Earnings Per Share | (0.39) X | |||
| Total Asset | 4.37 M | |||
| Retained Earnings | (388 M) | |||
| Current Asset | 12.58 M | |||
| Current Liabilities | 6.18 M | |||
About Navidea Biopharmaceutica Performance
By analyzing Navidea Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Navidea Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Navidea Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Navidea Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 11 people.Things to note about Navidea Biopharmaceutica performance evaluation
Checking the ongoing alerts about Navidea Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Navidea Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Navidea Biopharmaceutica is way too risky over 90 days horizon | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica appears to be risky and price may revert if volatility continues | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
- Analyzing Navidea Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Navidea Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Navidea Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Navidea Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Navidea Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Navidea Biopharmaceutica's pink sheet. These opinions can provide insight into Navidea Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Navidea Pink Sheet analysis
When running Navidea Biopharmaceutica's price analysis, check to measure Navidea Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Navidea Biopharmaceutica is operating at the current time. Most of Navidea Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Navidea Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Navidea Biopharmaceutica's price. Additionally, you may evaluate how the addition of Navidea Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |